Trade Vericel Corp Ord - VCEL CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 46.34 |
| Open | 46.21 |
| 1-Year Change | 50.47% |
| Day's Range | 45.95 - 46.6 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2024 | 46.05 | 1.39 | 3.11% | 44.66 | 46.71 | 44.66 |
| Apr 23, 2024 | 46.34 | 0.98 | 2.16% | 45.36 | 47.04 | 44.64 |
| Apr 22, 2024 | 45.35 | 1.28 | 2.90% | 44.07 | 45.60 | 43.71 |
| Apr 19, 2024 | 43.68 | 0.11 | 0.25% | 43.57 | 44.36 | 42.31 |
| Apr 18, 2024 | 43.79 | -2.16 | -4.70% | 45.95 | 46.00 | 43.62 |
| Apr 17, 2024 | 46.21 | -0.66 | -1.41% | 46.87 | 47.37 | 45.90 |
| Apr 16, 2024 | 47.42 | -0.02 | -0.04% | 47.44 | 48.52 | 46.70 |
| Apr 15, 2024 | 48.61 | 0.73 | 1.52% | 47.88 | 49.07 | 47.69 |
| Apr 12, 2024 | 47.80 | -0.15 | -0.31% | 47.95 | 48.78 | 46.87 |
| Apr 11, 2024 | 48.66 | -0.51 | -1.04% | 49.17 | 49.66 | 48.36 |
| Apr 10, 2024 | 49.09 | 0.36 | 0.74% | 48.73 | 49.67 | 47.95 |
| Apr 9, 2024 | 50.25 | 0.13 | 0.26% | 50.12 | 50.36 | 48.87 |
| Apr 8, 2024 | 50.12 | -1.17 | -2.28% | 51.29 | 51.29 | 50.11 |
| Apr 5, 2024 | 51.00 | 1.05 | 2.10% | 49.95 | 51.58 | 49.25 |
| Apr 4, 2024 | 50.32 | -1.00 | -1.95% | 51.32 | 51.75 | 50.18 |
| Apr 3, 2024 | 51.22 | 1.03 | 2.05% | 50.19 | 52.09 | 50.18 |
| Apr 2, 2024 | 51.18 | -1.04 | -1.99% | 52.22 | 52.22 | 51.13 |
| Apr 1, 2024 | 52.82 | 0.87 | 1.67% | 51.95 | 52.92 | 51.48 |
| Mar 28, 2024 | 51.95 | 0.00 | 0.00% | 51.95 | 52.37 | 51.45 |
| Mar 27, 2024 | 52.21 | 2.04 | 4.07% | 50.17 | 52.35 | 50.17 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Vericel Corp Ord Company profile
About Vericel Corp
Vericel Corporation is a commercial-stage biopharmaceutical company. The Company specializes in cell therapies and specialty biologics for the sports medicine and severe burn care. It operates in one reportable segment, the research, product development, manufacture, and distribution of cellular therapies for use in the treatment of specific diseases. It markets two autologous cell therapy products in the United States, which includes MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single, or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. The Epicel is a permanent skin replacement humanitarian use device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area (TBSA).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Vericel Corp revenues increased 26% to $156.2M. Net loss totaled $7.5M vs. income of $2.9M. Revenues reflect MACI segment increase of 18% to $111.6M, Epicel segment increase of 51% to $41.5M. Net loss reflects Stock-based Compensation in SGA increase from $10M to $26.5M (expense), Other Selling , General Expense increase of 21% to $71.1M (expense).
Equity composition
Common Stock no Par, 3/11, 62.5M auth., 38,618,037 issd. Insiders control approx. 0.63%. IPO: 2/97, 3M shares @ $7 byCowen & Company. 02/10 1-for-8 reverse split. 10/13, 1-for-20 Reverse Stock split.
| Industry: | Biopharmaceuticals |
64 Sidney St
CAMBRIDGE
MASSACHUSETTS 02139-4170
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com